25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

RXRX (Recursion) Stock Analysis
Buy, Hold or Sell?

Let's analyze Recursion together

I guess you are interested in Recursion Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Recursion’s Financial Insights
  • 📈 Technical Analysis (TA) – Recursion’s Price Targets

I'm going to help you getting a better view of Recursion Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Recursion Pharmaceuticals Inc

I send you an email if I find something interesting about Recursion Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Recursion (30 sec.)










1.2. What can you expect buying and holding a share of Recursion? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.19
Expected worth in 1 year
$3.44
How sure are you?
28.6%

+ What do you gain per year?

Total Gains per Share
$1.25
Return On Investment
23.6%

For what price can you sell your share?

Current Price per Share
$5.28
Expected price per share
$4.72 - $6.07
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Recursion (5 min.)




Live pricePrice per Share (EOD)
$5.28
Intrinsic Value Per Share
$-28.46 - $-33.94
Total Value Per Share
$-26.27 - $-31.76

2.2. Growth of Recursion (5 min.)




Is Recursion growing?

Current yearPrevious yearGrowGrow %
How rich?$933.9m$442.8m$326.5m42.4%

How much money is Recursion making?

Current yearPrevious yearGrowGrow %
Making money-$143.6m-$88.5m-$55.1m-38.4%
Net Profit Margin-1,595.7%-783.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Recursion (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#69 / 872

Most Revenue
#250 / 872

Most Profit
#853 / 872

Most Efficient
#733 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Recursion?

Welcome investor! Recursion's management wants to use your money to grow the business. In return you get a share of Recursion.

First you should know what it really means to hold a share of Recursion. And how you can make/lose money.

Speculation

The Price per Share of Recursion is $5.28. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Recursion.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Recursion, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.19. Based on the TTM, the Book Value Change Per Share is $0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Recursion.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.47-9.0%-0.34-6.4%-0.21-3.9%-0.23-4.4%-0.17-3.3%-0.17-3.2%
Usd Book Value Change Per Share-0.24-4.5%0.315.9%-0.02-0.3%0.091.6%0.112.1%0.102.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.24-4.5%0.315.9%-0.02-0.3%0.091.6%0.112.1%0.102.0%
Usd Price Per Share5.29-6.54-8.74-7.85-8.90-8.48-
Price to Earnings Ratio-2.79--5.59--10.53--10.14--15.25--14.52-
Price-to-Total Gains Ratio-22.39--11.56-18.44--11.97--33.93--33.93-
Price to Book Ratio2.42-4.01-8.48-6.92-7.16-6.82-
Price-to-Total Gains Ratio-22.39--11.56-18.44--11.97--33.93--33.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.28
Number of shares189
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.310.11
Usd Total Gains Per Share0.310.11
Gains per Quarter (189 shares)58.9920.68
Gains per Year (189 shares)235.9782.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1023622608373
204724620165156
307086980248239
409449340331322
50118011700414405
60141614060496488
70165216420579571
80188818780662654
90212421140745737
100236023500827820

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%6.012.02.030.0%6.012.03.028.6%6.012.03.028.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%6.012.02.030.0%6.012.03.028.6%6.012.03.028.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Recursion Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2360.312-176%-0.017-93%0.086-375%0.109-316%0.104-327%
Book Value Per Share--2.1891.803+21%1.038+111%1.287+70%0.988+122%0.941+133%
Current Ratio--4.1144.587-10%4.374-6%4.860-15%6.642-38%6.326-35%
Debt To Asset Ratio--0.2840.274+4%0.294-3%0.300-5%0.388-27%0.370-23%
Debt To Equity Ratio--0.3980.377+5%0.416-4%0.432-8%0.299+33%0.285+39%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--2386615352.3202993769167.280-20%3916121082.400-39%3576021458.667-33%5035543210.900-53%5035543210.900-53%
Eps---0.474-0.337-29%-0.207-56%-0.230-52%-0.174-63%-0.168-65%
Ev To Ebitda Ratio---3.118-6.528+109%-11.793+278%-11.682+275%-21.869+601%-21.869+601%
Ev To Sales Ratio--40.46574.975-46%85.912-53%82.347-51%285.869-86%285.869-86%
Free Cash Flow Per Share---0.314-0.233-26%-0.194-38%-0.196-38%-0.136-57%-0.132-58%
Free Cash Flow To Equity Per Share---0.219-0.039-82%-0.105-52%-0.071-67%0.021-1151%0.018-1287%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---33.944----------
Intrinsic Value_10Y_min---28.457----------
Intrinsic Value_1Y_max---1.163----------
Intrinsic Value_1Y_min---1.141----------
Intrinsic Value_3Y_max---5.200----------
Intrinsic Value_3Y_min---4.930----------
Intrinsic Value_5Y_max---11.294----------
Intrinsic Value_5Y_min---10.336----------
Market Cap2253181962.2400%2257449352.3202788739417.280-19%3728632082.400-39%3351679292.000-33%3799044018.720-41%3618137160.686-38%
Net Profit Margin---13.733-15.957+16%-7.834-43%-9.784-29%-17.110+25%-30.918+125%
Operating Margin----12.4790%-8.2170%-8.7970%-16.2990%-29.9060%
Operating Ratio--13.97917.115-18%9.569+46%11.200+25%24.672-43%48.247-71%
Pb Ratio2.4130%2.4174.011-40%8.484-72%6.917-65%7.164-66%6.823-65%
Pe Ratio-2.782+0%-2.787-5.592+101%-10.528+278%-10.142+264%-15.249+447%-14.523+421%
Price Per Share5.2800%5.2906.535-19%8.738-39%7.854-33%8.903-41%8.479-38%
Price To Free Cash Flow Ratio-4.210+0%-4.218-7.801+85%-11.434+171%-10.891+158%-15.159+259%-14.437+242%
Price To Total Gains Ratio-22.345+0%-22.388-11.557-48%18.440-221%-11.973-47%-33.930+52%-33.930+52%
Quick Ratio--3.8504.198-8%4.024-4%4.605-16%6.903-44%6.574-41%
Return On Assets---0.155-0.134-14%-0.142-8%-0.123-21%-0.100-36%-0.095-39%
Return On Equity---0.217-0.185-15%-0.201-7%-0.175-19%-0.152-30%-0.156-28%
Total Gains Per Share---0.2360.312-176%-0.017-93%0.086-375%0.109-316%0.104-327%
Usd Book Value--933947000.000769434250.000+21%442879250.000+111%549237333.333+70%421488900.000+122%401418000.000+133%
Usd Book Value Change Per Share---0.2360.312-176%-0.017-93%0.086-375%0.109-316%0.104-327%
Usd Book Value Per Share--2.1891.803+21%1.038+111%1.287+70%0.988+122%0.941+133%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--2386615352.3202993769167.280-20%3916121082.400-39%3576021458.667-33%5035543210.900-53%5035543210.900-53%
Usd Eps---0.474-0.337-29%-0.207-56%-0.230-52%-0.174-63%-0.168-65%
Usd Free Cash Flow---133789000.000-99513750.000-26%-82657250.000-38%-83439083.333-38%-58013400.000-57%-56131857.143-58%
Usd Free Cash Flow Per Share---0.314-0.233-26%-0.194-38%-0.196-38%-0.136-57%-0.132-58%
Usd Free Cash Flow To Equity Per Share---0.219-0.039-82%-0.105-52%-0.071-67%0.021-1151%0.018-1287%
Usd Market Cap2253181962.2400%2257449352.3202788739417.280-19%3728632082.400-39%3351679292.000-33%3799044018.720-41%3618137160.686-38%
Usd Price Per Share5.2800%5.2906.535-19%8.738-39%7.854-33%8.903-41%8.479-38%
Usd Profit---202487000.000-143652000.000-29%-88528000.000-56%-97570916.667-52%-74094450.000-63%-71443476.190-65%
Usd Revenue--14745000.00014938750.000-1%11450750.000+29%12672833.333+16%8548600.000+72%8144380.952+81%
Usd Total Gains Per Share---0.2360.312-176%-0.017-93%0.086-375%0.109-316%0.104-327%
 EOD+3 -5MRQTTM+8 -28YOY+9 -283Y+9 -285Y+11 -2610Y+11 -26

3.3 Fundamental Score

Let's check the fundamental score of Recursion Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.782
Price to Book Ratio (EOD)Between0-12.413
Net Profit Margin (MRQ)Greater than0-13.733
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.850
Current Ratio (MRQ)Greater than14.114
Debt to Asset Ratio (MRQ)Less than10.284
Debt to Equity Ratio (MRQ)Less than10.398
Return on Equity (MRQ)Greater than0.15-0.217
Return on Assets (MRQ)Greater than0.05-0.155
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Recursion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.454
Ma 20Greater thanMa 505.163
Ma 50Greater thanMa 1004.858
Ma 100Greater thanMa 2005.615
OpenGreater thanClose5.560
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Fundamental data was last updated by Penke on 2025-07-12 12:30:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Recursion earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Recursion to the Biotechnology industry mean.
  • A Net Profit Margin of -1,373.3% means that $-13.73 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Recursion Pharmaceuticals Inc:

  • The MRQ is -1,373.3%. The company is making a huge loss. -2
  • The TTM is -1,595.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,373.3%TTM-1,595.7%+222.4%
TTM-1,595.7%YOY-783.4%-812.3%
TTM-1,595.7%5Y-1,711.0%+115.3%
5Y-1,711.0%10Y-3,091.8%+1,380.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,373.3%-91.7%-1,281.6%
TTM-1,595.7%-140.3%-1,455.4%
YOY-783.4%-196.4%-587.0%
3Y-978.4%-247.9%-730.5%
5Y-1,711.0%-343.3%-1,367.7%
10Y-3,091.8%-488.1%-2,603.7%
4.3.1.2. Return on Assets

Shows how efficient Recursion is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Recursion to the Biotechnology industry mean.
  • -15.5% Return on Assets means that Recursion generated $-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Recursion Pharmaceuticals Inc:

  • The MRQ is -15.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.5%TTM-13.4%-2.1%
TTM-13.4%YOY-14.2%+0.8%
TTM-13.4%5Y-10.0%-3.4%
5Y-10.0%10Y-9.5%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.5%-11.5%-4.0%
TTM-13.4%-11.5%-1.9%
YOY-14.2%-11.4%-2.8%
3Y-12.3%-11.7%-0.6%
5Y-10.0%-11.9%+1.9%
10Y-9.5%-13.7%+4.2%
4.3.1.3. Return on Equity

Shows how efficient Recursion is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Recursion to the Biotechnology industry mean.
  • -21.7% Return on Equity means Recursion generated $-0.22 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Recursion Pharmaceuticals Inc:

  • The MRQ is -21.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.7%TTM-18.5%-3.2%
TTM-18.5%YOY-20.1%+1.6%
TTM-18.5%5Y-15.2%-3.3%
5Y-15.2%10Y-15.6%+0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.7%-13.6%-8.1%
TTM-18.5%-14.8%-3.7%
YOY-20.1%-14.4%-5.7%
3Y-17.5%-16.8%-0.7%
5Y-15.2%-17.5%+2.3%
10Y-15.6%-19.5%+3.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Recursion Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Recursion is operating .

  • Measures how much profit Recursion makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Recursion to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Recursion Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,247.9%+1,247.9%
TTM-1,247.9%YOY-821.7%-426.2%
TTM-1,247.9%5Y-1,629.9%+382.0%
5Y-1,629.9%10Y-2,990.6%+1,360.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--221.8%+221.8%
TTM-1,247.9%-250.7%-997.2%
YOY-821.7%-208.5%-613.2%
3Y-879.7%-220.2%-659.5%
5Y-1,629.9%-342.4%-1,287.5%
10Y-2,990.6%-462.5%-2,528.1%
4.3.2.2. Operating Ratio

Measures how efficient Recursion is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 13.98 means that the operating costs are $13.98 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Recursion Pharmaceuticals Inc:

  • The MRQ is 13.979. The company is inefficient in keeping operating costs low. -1
  • The TTM is 17.115. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ13.979TTM17.115-3.137
TTM17.115YOY9.569+7.546
TTM17.1155Y24.672-7.556
5Y24.67210Y48.247-23.575
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.9792.097+11.882
TTM17.1152.684+14.431
YOY9.5693.076+6.493
3Y11.2003.524+7.676
5Y24.6724.724+19.948
10Y48.2476.445+41.802
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Recursion Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Recursion is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.11 means the company has $4.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Recursion Pharmaceuticals Inc:

  • The MRQ is 4.114. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.587. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.114TTM4.587-0.473
TTM4.587YOY4.374+0.213
TTM4.5875Y6.642-2.055
5Y6.64210Y6.326+0.316
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1143.638+0.476
TTM4.5873.846+0.741
YOY4.3744.140+0.234
3Y4.8604.688+0.172
5Y6.6425.722+0.920
10Y6.3266.144+0.182
4.4.3.2. Quick Ratio

Measures if Recursion is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Recursion to the Biotechnology industry mean.
  • A Quick Ratio of 3.85 means the company can pay off $3.85 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Recursion Pharmaceuticals Inc:

  • The MRQ is 3.850. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.198. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.850TTM4.198-0.348
TTM4.198YOY4.024+0.174
TTM4.1985Y6.903-2.705
5Y6.90310Y6.574+0.329
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8502.826+1.024
TTM4.1983.116+1.082
YOY4.0243.786+0.238
3Y4.6054.311+0.294
5Y6.9035.702+1.201
10Y6.5746.335+0.239
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Recursion Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Recursion assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Recursion to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.28 means that Recursion assets are financed with 28.4% credit (debt) and the remaining percentage (100% - 28.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Recursion Pharmaceuticals Inc:

  • The MRQ is 0.284. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.274. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.284TTM0.274+0.011
TTM0.274YOY0.294-0.020
TTM0.2745Y0.388-0.114
5Y0.38810Y0.370+0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2840.327-0.043
TTM0.2740.349-0.075
YOY0.2940.332-0.038
3Y0.3000.340-0.040
5Y0.3880.346+0.042
10Y0.3700.378-0.008
4.5.4.2. Debt to Equity Ratio

Measures if Recursion is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Recursion to the Biotechnology industry mean.
  • A Debt to Equity ratio of 39.8% means that company has $0.40 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Recursion Pharmaceuticals Inc:

  • The MRQ is 0.398. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.377. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.398TTM0.377+0.020
TTM0.377YOY0.416-0.038
TTM0.3775Y0.299+0.078
5Y0.29910Y0.285+0.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3980.383+0.015
TTM0.3770.438-0.061
YOY0.4160.414+0.002
3Y0.4320.450-0.018
5Y0.2990.457-0.158
10Y0.2850.512-0.227
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Recursion generates.

  • Above 15 is considered overpriced but always compare Recursion to the Biotechnology industry mean.
  • A PE ratio of -2.79 means the investor is paying $-2.79 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Recursion Pharmaceuticals Inc:

  • The EOD is -2.782. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.787. Based on the earnings, the company is expensive. -2
  • The TTM is -5.592. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.782MRQ-2.787+0.005
MRQ-2.787TTM-5.592+2.805
TTM-5.592YOY-10.528+4.936
TTM-5.5925Y-15.249+9.656
5Y-15.24910Y-14.523-0.726
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.782-2.399-0.383
MRQ-2.787-2.092-0.695
TTM-5.592-2.625-2.967
YOY-10.528-3.784-6.744
3Y-10.142-3.762-6.380
5Y-15.249-6.363-8.886
10Y-14.523-7.055-7.468
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Recursion Pharmaceuticals Inc:

  • The EOD is -4.210. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.218. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.801. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.210MRQ-4.218+0.008
MRQ-4.218TTM-7.801+3.583
TTM-7.801YOY-11.434+3.633
TTM-7.8015Y-15.159+7.358
5Y-15.15910Y-14.437-0.722
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.210-3.299-0.911
MRQ-4.218-2.742-1.476
TTM-7.801-3.801-4.000
YOY-11.434-4.402-7.032
3Y-10.891-5.140-5.751
5Y-15.159-8.483-6.676
10Y-14.437-9.296-5.141
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Recursion is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.42 means the investor is paying $2.42 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Recursion Pharmaceuticals Inc:

  • The EOD is 2.413. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.417. Based on the equity, the company is underpriced. +1
  • The TTM is 4.011. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.413MRQ2.417-0.005
MRQ2.417TTM4.011-1.593
TTM4.011YOY8.484-4.474
TTM4.0115Y7.164-3.154
5Y7.16410Y6.823+0.341
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4132.113+0.300
MRQ2.4171.856+0.561
TTM4.0112.125+1.886
YOY8.4842.454+6.030
3Y6.9172.492+4.425
5Y7.1643.668+3.496
10Y6.8234.364+2.459
4.6.2. Total Gains per Share

2.4. Latest News of Recursion Pharmaceuticals Inc

Does Recursion Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Recursion Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-12
10:30
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch.Read
2025-07-09
14:16
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25MRead
2025-07-08
14:00
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for HypophosphatasiaRead
2025-06-28
18:00
Why This Wildcard Stock Could Be a Future StarRead
2025-06-27
23:50
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to NoteRead
2025-06-20
23:50
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsRead
2025-06-16
14:24
Recursion Pharmaceuticals price target lowered to $5 by Morgan StanleyRead
2025-06-16
11:30
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Recursion Pharmaceuticals Inc.

4.8.1. Institutions holding Recursion Pharmaceuticals Inc

Institutions are holding 74.162% of the shares of Recursion Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31ARK Investment Management LLC8.56481.84353481550224691047.6333
2025-03-31Vanguard Group Inc7.9430.003132287977-1722017-5.0633
2025-03-31Baillie Gifford & Co Limited.6.00080.112624393015-471043-1.8945
2025-03-31BlackRock Inc5.78270.002623506589699530.2985
2025-03-31SoftBank Group Corp3.60830.26481466749100
2025-03-31State Street Corp3.2190.0029130852585068984.0299
2025-03-31Mubadala Investment Company PJSC3.19460.391298592700
2025-03-31Novo A/S2.37773.88929665128-449505-4.4441
2025-03-31MIC Capital Management UK LLP2.372510.39429644032-10
2025-03-31Sumitomo Mitsui Trust Group Inc2.08590.03178479284-501317-5.5822
2025-03-31Nikko Asset Management Americas Inc2.06820.57238407334-501317-5.6273
2025-03-31NVIDIA Corp1.89583.5538770636300
2025-03-31FMR Inc1.68440.00236846842-225339-3.1863
2025-03-31Geode Capital Management, LLC1.58530.002764439803568315.862
2025-03-31UBS Asset Mgmt Americas Inc1.57650.008764085244149346183.6662
2025-03-31Data Collective IV GP, LLC1.461536.1672594112000
2025-03-31UBS Group AG1.37020.00545569782256513785.3724
2025-03-31Morgan Stanley - Brokerage Accounts1.23260.00195010433214990675.1577
2025-03-31DCVC Opportunity Fund II GP, LLC0.97225.6513395114100
2025-03-31Exor Investments (UK) LLP0.90410.5078367507700
Total 59.899983.408243490799+8396636+3.4%

4.9.2. Funds holding Recursion Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31ARK Disruptive Innovation Full Composite4.74372.03141928276810047395.497
2025-05-31ARK Innovation ETF4.52431.384618391219-261268-1.4007
2025-03-31Scottish Mortgage Ord4.4710.54221817438400
2025-03-31ARK Genomic Revolution3.10136.94581260661810988309.5486
2025-05-31ARK Genomic Revolution ETF2.76375.448311234452-529893-4.5042
2025-05-31Vanguard Total Stock Mkt Idx Inv2.72920.0025110942531204491.0976
2025-05-31Vanguard Small Cap Index2.14050.02448701055320150.3693
2025-05-31SPDR® S&P Biotech ETF1.6940.61356885889407260.595
2025-05-31iShares Russell 2000 ETF1.54960.0428629921500
2025-05-31Vanguard Small Cap Growth Index Inv1.18290.05684808343-6362-0.1321
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr1.11570.01744535384319710.7099
2025-04-30Nikko AM ARK Disruptive Innovation A USD1.06470.9667432790300
2024-12-31Baillie Gifford US Equity Growth0.90160.2628366489100
2025-03-31Vanguard US Growth Investor0.80160.0418325858700
2025-04-30Nikko AM ARK Pstv Chg Innovt P JPY Acc0.74510.91753028830-56411-1.8284
2025-03-31Fidelity Small Cap Index0.61810.0552512610416691.6864
2025-05-31iShares Russell 2000 Growth ETF0.53760.0827218517700
2025-05-31iShares Biotechnology ETF0.43170.1469175502600
2025-04-30Fidelity Extended Market Index0.4030.02541638177224811.3914
2025-04-30UBS Lux Dgtl Hlth Eq Fd seeding P acc0.3911.19871589248-60752-3.6819
Total 35.910320.8072145974029+1478194+1.0%

5.3. Insider Transactions

Insiders are holding 5.098% of the shares of Recursion Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-13Michael SecoraSELL150007.66
2024-11-12Blake BorgesonSELL114477.64
2024-10-29Blake BorgesonSELL114476.72
2024-10-24Tina MarriottSELL60006.31
2024-10-15Blake BorgesonSELL114476.67
2024-10-08Michael SecoraSELL150006.32
2024-10-02Christopher GibsonSELL200006.16
2024-10-01Blake BorgesonSELL114476.22
2024-09-26Tina MarriottSELL60007
2024-09-17Blake BorgesonSELL114476.84
2024-09-10Michael SecoraSELL150006.17
2024-09-04Christopher GibsonSELL200006.04
2024-09-03Blake BorgesonSELL114476.27
2024-08-29Tina MarriottSELL60007.56
2024-08-20Blake BorgesonSELL114477.12
2024-08-13Michael SecoraSELL150006.35
2024-08-07Christopher GibsonSELL300007.1
2024-08-06Blake BorgesonSELL114476.82
2024-07-25Tina MarriottSELL60008.13
2024-07-23Blake BorgesonSELL114478.48
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Total Other Income Expense Net 4,188-1,7082,4801992,6792,1904,869-16,146-11,277



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,305,234
Total Liabilities371,287
Total Stockholder Equity933,947
 As reported
Total Liabilities 371,287
Total Stockholder Equity+ 933,947
Total Assets = 1,305,234

Assets

Total Assets1,305,234
Total Current Assets584,145
Long-term Assets721,089
Total Current Assets
Cash And Cash Equivalents 500,453
Net Receivables 46,124
Other Current Assets 37,568
Total Current Assets  (as reported)584,145
Total Current Assets  (calculated)584,145
+/-0
Long-term Assets
Property Plant Equipment 204,777
Goodwill 158,112
Intangible Assets 335,790
Long-term Assets Other 20,407
Long-term Assets  (as reported)721,089
Long-term Assets  (calculated)719,086
+/- 2,003

Liabilities & Shareholders' Equity

Total Current Liabilities141,981
Long-term Liabilities229,306
Total Stockholder Equity933,947
Total Current Liabilities
Short-term Debt 20,440
Short Long Term Debt 8,587
Accounts payable 25,086
Other Current Liabilities 56,804
Total Current Liabilities  (as reported)141,981
Total Current Liabilities  (calculated)110,917
+/- 31,064
Long-term Liabilities
Long term Debt 16,446
Capital Lease Obligations 67,877
Long-term Liabilities Other 4,790
Long-term Liabilities  (as reported)229,306
Long-term Liabilities  (calculated)89,113
+/- 140,193
Total Stockholder Equity
Common Stock4
Retained Earnings -1,633,694
Accumulated Other Comprehensive Income 14,145
Other Stockholders Equity 2,553,492
Total Stockholder Equity (as reported)933,947
Total Stockholder Equity (calculated)933,947
+/-0
Other
Capital Stock4
Cash and Short Term Investments 500,453
Common Stock Shares Outstanding 402,772
Current Deferred Revenue39,651
Liabilities and Stockholders Equity 1,305,234
Net Debt -407,543
Net Invested Capital 958,980
Net Working Capital 442,164
Property Plant and Equipment Gross 204,777
Short Long Term Debt Total 92,910



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
298,585
271,943
698,590
658,606
610,345
734,319
672,515
611,533
701,288
627,366
666,699
630,825
653,699
557,847
775,861
726,499
1,448,598
1,305,234
1,305,2341,448,598726,499775,861557,847653,699630,825666,699627,366701,288611,533672,515734,319610,345658,606698,590271,943298,585000
   > Total Current Assets 
69,883
0
0
269,478
221,822
647,635
600,870
534,718
619,455
545,996
481,618
569,814
492,125
431,020
410,522
438,137
343,615
522,375
474,172
714,269
584,145
584,145714,269474,172522,375343,615438,137410,522431,020492,125569,814481,618545,996619,455534,718600,870647,635221,822269,4780069,883
       Cash And Cash Equivalents 
-69,883
0
0
262,126
214,088
632,738
394,721
285,116
507,891
453,875
454,646
549,912
473,145
405,870
387,322
394,796
299,521
476,124
427,647
594,350
500,453
500,453594,350427,647476,124299,521394,796387,322405,870473,145549,912454,646453,875507,891285,116394,721632,738214,088262,12600-69,883
       Short-term Investments 
139,766
0
0
0
0
0
184,189
231,446
83,214
61,561
0
0
0
0
0
0
0
0
0
0
0
0000000000061,56183,214231,446184,18900000139,766
       Net Receivables 
0
0
0
156
71
49
2,282
9,090
11,397
11,680
11,635
2,753
2,057
3,051
3,164
3,094
2,599
2,526
2,255
49,166
46,124
46,12449,1662,2552,5262,5993,0943,1643,0512,0572,75311,63511,68011,3979,0902,2824971156000
       Other Current Assets 
0
0
0
4,155
7,663
14,848
19,678
9,066
16,953
18,880
15,337
17,149
16,923
22,099
20,036
43,478
41,495
45,508
44,270
70,753
37,568
37,56870,75344,27045,50841,49543,47820,03622,09916,92317,14915,33718,88016,9539,06619,67814,8487,6634,155000
   > Long-term Assets 
-69,883
0
0
29,107
50,121
50,955
57,736
75,627
114,864
126,519
129,915
131,474
135,241
235,679
220,303
215,562
214,232
253,486
252,327
734,329
721,089
721,089734,329252,327253,486214,232215,562220,303235,679135,241131,474129,915126,519114,86475,62757,73650,95550,12129,10700-69,883
       Property Plant Equipment 
0
0
0
25,967
44,642
48,549
55,439
64,725
104,005
116,151
119,503
121,447
125,120
124,667
120,310
120,173
122,217
156,283
159,189
233,213
204,777
204,777233,213159,189156,283122,217120,173120,310124,667125,120121,447119,503116,151104,00564,72555,43948,54944,64225,967000
       Goodwill 
0
0
0
801
801
801
801
801
801
801
801
801
801
60,516
52,750
52,056
52,056
52,056
52,056
148,873
158,112
158,112148,87352,05652,05652,05652,05652,75060,516801801801801801801801801801801000
       Intangible Assets 
0
0
0
2,490
2,414
2,338
1,461
1,385
1,309
1,233
1,457
1,306
1,318
42,757
39,459
36,443
33,076
38,210
34,093
335,855
335,790
335,790335,85534,09338,21033,07636,44339,45942,7571,3181,3061,4571,2331,3091,3851,4612,3382,4142,490000
       Long-term Assets Other 
-69,883
0
0
650
3,065
68
35
35
36
8,334
8,154
7,920
8,002
7,739
7,784
-36,182
254
308
6,989
14,454
20,407
20,40714,4546,989308254-36,1827,7847,7398,0027,9208,1548,334363535683,06565000-69,883
> Total Liabilities 
0
0
0
504,874
504,974
55,876
59,574
67,407
240,753
234,936
223,499
215,482
197,191
197,736
192,858
190,263
156,696
191,412
201,940
413,816
371,287
371,287413,816201,940191,412156,696190,263192,858197,736197,191215,482223,499234,936240,75367,40759,57455,876504,974504,874000
   > Total Current Liabilities 
0
0
0
23,099
26,854
29,540
42,943
46,658
85,705
96,653
83,036
100,265
92,150
113,959
94,118
93,171
73,920
86,083
108,888
187,472
141,981
141,981187,472108,88886,08373,92093,17194,118113,95992,150100,26583,03696,65385,70546,65842,94329,54026,85423,099000
       Short-term Debt 
0
0
0
1,540
2,644
3,634
2,920
1,506
8,264
10,577
11,177
6,049
9,541
11,114
11,405
12,273
6,117
25,323
16,452
22,220
20,440
20,44022,22016,45225,3236,11712,27311,40511,1149,5416,04911,17710,5778,2641,5062,9203,6342,6441,540000
       Short Long Term Debt 
0
0
0
1,073
2,145
3,135
88
90
92
93
95
97
661
676
695
41
55
8,109
8,219
8,425
8,587
8,5878,4258,2198,10955416956766619795939290883,1352,1451,073000
       Accounts payable 
0
0
0
1,074
3,125
3,196
6,326
2,819
4,162
3,176
3,890
4,586
4,247
2,086
4,265
3,953
5,115
3,762
2,260
21,613
25,086
25,08621,6132,2603,7625,1153,9534,2652,0864,2474,5863,8903,1764,1622,8196,3263,1963,1251,074000
       Other Current Liabilities 
0
0
0
20,207
11,085
12,710
25,113
32,333
19,032
19,119
21,216
32,904
20,601
27,654
34,451
40,519
26,070
24,794
40,597
81,872
56,804
56,80481,87240,59724,79426,07040,51934,45127,65420,60132,90421,21619,11919,03232,33325,11312,71011,08520,207000
   > Long-term Liabilities 
0
0
0
481,775
478,120
26,336
16,631
20,749
155,048
138,283
140,463
115,217
105,041
83,777
98,740
97,092
82,776
105,329
93,052
226,344
229,306
229,306226,34493,052105,32982,77697,09298,74083,777105,041115,217140,463138,283155,04820,74916,63126,336478,120481,775000
       Long term Debt Total 
0
0
0
0
0
0
656
633
610
586
561
0
1,179
1,155
0
0
0
0
0
0
0
00000001,1551,1790561586610633656000000
       Warrants
0
0
0
0
448,312
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000448,3120000
       Other Liabilities 
0
0
0
0
16,917
14,486
12,515
20,116
107,121
89,934
93,909
70,261
57,091
36,772
0
0
0
0
0
0
0
000000036,77257,09170,26193,90989,934107,12120,11612,51514,48616,9170000
       Deferred Long Term Liability 
0
0
0
0
2,750
2,819
3,348
4,110
0
0
0
0
0
4,336
0
0
0
0
0
0
0
00000004,336000004,1103,3482,8192,7500000
> Total Stockholder Equity
76,844
0
0
-206,289
-233,031
642,714
599,032
542,938
493,566
437,579
388,034
485,806
430,175
468,963
437,967
463,436
401,151
584,449
524,559
1,034,782
933,947
933,9471,034,782524,559584,449401,151463,436437,967468,963430,175485,806388,034437,579493,566542,938599,032642,714-233,031-206,2890076,844
   Common Stock
0
0
0
0
0
2
2
2
2
2
2
2
2
2
2
2
2
3
3
4
4
443322222222222200000
   Retained Earnings -1,633,694-1,431,283-1,252,377-1,156,535-1,058,995-967,622-874,626-781,609-704,883-639,556-582,064-521,619-456,059-400,080-335,147-287,719-244,318-213,601000
   Capital Surplus 
0
0
0
0
11,287
930,431
934,175
943,142
949,932
959,393
970,096
0
1,135,056
1,250,570
0
0
0
0
0
0
0
00000001,250,5701,135,0560970,096959,393949,932943,142934,175930,43111,2870000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
-441,000
11,287
231,841
934,175
943,142
949,932
959,393
970,096
1,125,360
1,135,056
1,250,570
1,312,591
1,431,056
1,460,144
1,740,981
1,776,933
2,473,698
2,553,492
2,553,4922,473,6981,776,9331,740,9811,460,1441,431,0561,312,5911,250,5701,135,0561,125,360970,096959,393949,932943,142934,175231,84111,287-441,000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue58,839
Cost of Revenue-45,238
Gross Profit13,60113,601
 
Operating Income (+$)
Gross Profit13,601
Operating Expense-492,605
Operating Income-479,004-479,004
 
Operating Expense (+$)
Research Development314,421
Selling General Administrative178,184
Selling And Marketing Expenses0
Operating Expense492,605492,605
 
Net Interest Income (+$)
Interest Income15,758
Interest Expense-1,572
Other Finance Cost-0
Net Interest Income14,186
 
Pretax Income (+$)
Operating Income-479,004
Net Interest Income14,186
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-464,788-493,220
EBIT - interestExpense = -464,788
-464,788
-462,089
Interest Expense1,572
Earnings Before Interest and Taxes (EBIT)-463,216-463,216
Earnings Before Interest and Taxes (EBITDA)-426,722
 
After tax Income (+$)
Income Before Tax-464,788
Tax Provision--1,127
Net Income From Continuing Ops-463,661-463,661
Net Income-463,661
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses537,843
Total Other Income/Expenses Net14,216-14,186
 

Technical Analysis of Recursion
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Recursion. The general trend of Recursion is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Recursion's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Recursion Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Recursion Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 5.93 < 6 < 6.07.

The bearish price targets are: 5.48 > 4.75 > 4.72.

Know someone who trades $RXRX? Share this with them.👇

Recursion Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Recursion Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Recursion Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Recursion Pharmaceuticals Inc. The current macd is 0.14016268.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Recursion price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Recursion. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Recursion price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Recursion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartRecursion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Recursion Pharmaceuticals Inc. The current adx is 26.52.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Recursion shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Recursion Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Recursion Pharmaceuticals Inc. The current sar is 4.84546168.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Recursion Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Recursion Pharmaceuticals Inc. The current rsi is 52.45. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Recursion Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartRecursion Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Recursion Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Recursion price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Recursion Pharmaceuticals Inc Daily Stochastic Oscillator ChartRecursion Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Recursion Pharmaceuticals Inc. The current cci is 84.66.

Recursion Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartRecursion Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Recursion Pharmaceuticals Inc. The current cmo is 3.1492859.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Recursion Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartRecursion Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Recursion Pharmaceuticals Inc. The current willr is -51.69498836.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Recursion is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Recursion Pharmaceuticals Inc Daily Williams %R ChartRecursion Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Recursion Pharmaceuticals Inc. The current atr is 0.41939663.

Recursion Pharmaceuticals Inc Daily Average True Range (ATR) ChartRecursion Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Recursion Pharmaceuticals Inc. The current obv is 132,398,396.

Recursion Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartRecursion Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Recursion Pharmaceuticals Inc. The current mfi is 56.97.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Recursion Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartRecursion Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Recursion Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Recursion Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Recursion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.454
Ma 20Greater thanMa 505.163
Ma 50Greater thanMa 1004.858
Ma 100Greater thanMa 2005.615
OpenGreater thanClose5.560
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Recursion with someone you think should read this too:
  • Are you bullish or bearish on Recursion? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Recursion? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Recursion Pharmaceuticals Inc

I send you an email if I find something interesting about Recursion Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Recursion Pharmaceuticals Inc.

Receive notifications about Recursion Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.